Evidence map›Paper›PMID 29193104›Full record

Trial reportTransfusion2018

Transfusion strategy for weak D Type 4.0 based on RHD alleles and RH haplotypes in Tunisia.

Mouna Ouchari, Kshitij Srivastava, Houda Romdhane, Saloua Jemni Yacoub, Willy Albert Flegel

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Transfusion, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. A Bioinformatically Initiated Approach to Evaluate GATA1 Regulatory Regions in Samples with Weak D, Del, or D- Phenotypes Despite NormalTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2024
    Article
  3. Proceed with care: the "uncommon" serologic weak D phenotypes.Blood transfusion = Trasfusione del sangue · 2021
    Article
  4. What constitutes the most cautious approach for a pregnant person with weak D type 4.0?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2021
    Article
  5. Article
  6. Article
  7. Implementation of MolecularTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2019
    Article
  8. Article
  9. Article
  10. Article
  11. Genotyping in Sickle Cell Disease Patients: The French Strategy.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2018
    Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 3 countries.

Mouna OuchariDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland.
Kshitij SrivastavaDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland.
Houda RomdhaneRegional Blood Transfusion Center, Sousse, Tunisia.
Saloua Jemni YacoubRegional Blood Transfusion Center, Sousse, Tunisia.
Willy Albert FlegelDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-1631-7198
National Institutes of Health Clinical Center · USNational Blood Transfusion Service · NG

Funding

Intramural NIH HHS Z99 CL999999
6 · The paper itself

Abstract

backgroundWith more than 460 RHD alleles, this gene is the most complex and polymorphic among all blood group systems. The Tunisian population has the largest known prevalence of weak D Type 4.0 alleles, occurring in one of 105 RH haplotypes. We aimed to establish a rationale for the transfusion strategy of weak D Type 4.0 in Tunisia. STUDY DESIGN AND

methodsDonors were randomly screened for the serologic weak D phenotype. The RHD coding sequence and parts of the introns were sequenced. To establish the RH haplotype, the RHCE gene was tested for characteristic single-nucleotide positions.

resultsWe determined all RHD alleles and the RH haplotypes coding for the serologic weak D phenotype among 13,431 Tunisian donations. A serologic weak D phenotype was found in 67 individuals (0.50%). Among them, 60 carried a weak D Type 4 allele: 53 weak D Type 4.0, six weak D Type 4.2.2 (DAR), and one weak D Type 4.1. An additional four donors had one variant allele each: DVII, weak D Type 1, weak D Type 3, and weak D type 100, while three donors showed a normal RHD sequence. The weak D Type 4.0 was most often linked to RHCE*ceVS.04.01, weak D Type 4.2.2 to RHCE*ceAR, and weak D Type 4.1 to RHCE*ceVS.02, while the other RHD alleles were linked to one of the common RHCE alleles.

conclusionsAmong the weak D phenotypes in Tunisia, no novel RHD allele was found and almost 90% were caused by alleles of the weak D Type 4 cluster, of which 88% represented the weak D Type 4.0 allele. Based on established RH haplotypes for variant RHD and RHCE alleles and the lack of adverse clinical reports, we recommend D+ transfusions for patients with weak D Type 4.0 in Tunisia.

Indexed as

AllelesBlood TransfusionGene FrequencyHaplotypesFemaleHumansMalePrevalenceRh-Hr Blood-Group SystemTunisiaRHCE protein, humanRh-Hr Blood-Group SystemRho(D) antigen

Identifiers

PMID29193104
PMCPMC5803429
OpenAlexW2769224301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.